What is Eos SENOLYTIX?
Eos SENOLYTIX is a Houston-based longevity company founded in 2017, dedicated to developing novel gerotherapeutics. The company leverages advanced technologies and proprietary gerotherapeutic peptides to target the biological processes of aging, aiming to rejuvenate aged cells and enhance mitochondrial function. Their primary focus is on creating breakthrough therapies for age-related chronic diseases, including cancer and diabetes, through a network of specialized affiliates.
How much funding has Eos SENOLYTIX raised?
Eos SENOLYTIX has raised a total of $750K across 1 funding round:
Private Equity
$750K
Private Equity (2026): $750K, investors not publicly disclosed
What's next for Eos SENOLYTIX?
With this major enterprise-level funding, Eos SENOLYTIX is poised for accelerated growth and the expansion of its gerotherapeutic pipeline. The strategic investment signals strong market confidence in their approach to longevity medicine, suggesting a focus on scaling operations, advancing clinical trials, and potentially forging new partnerships to bring their innovative therapies to a wider market. This backing will likely fuel further research into extending healthspan and lifespan.
See full Eos SENOLYTIX company page
